Regenerative Medicine Market Set to Hit USD 194.9 Billion by 2032, Driven by Robust CAGR of 19.4%
January 08, 2024 07:35 ET
|
Market.Us
New York, Jan. 08, 2024 (GLOBE NEWSWIRE) -- According to the market.us, the anticipated value of the Global Regenerative Medicine Market is projected to reach approximately USD 194.9 billion by the...
Westlake University Establishes School of Medicine
December 07, 2023 09:00 ET
|
Westlake University
Hangzhou, China, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Recently, the Board of Trustees of Westlake University decided to establish the Westlake University School of Medicine and appoint Professor Chen...
Venous Stents Market to Reach USD 2.31 billion by 2032 | Amid Rising Demand From Hospitals and Cardiac Centers - Market.us
September 28, 2023 06:53 ET
|
Market.Us
New York, Sept. 28, 2023 (GLOBE NEWSWIRE) -- According Markte.us, The Venous Stents market is estimated to be worth USD 1.02 Billion in 2022 and may attain USD 2.31 Billion by 2032. During the...
Global Newborn Screening Instruments Market Size Envisions USD 1,552 Million by 2030, with a Strong 7.80% CAGR
September 18, 2023 09:43 ET
|
Zion Market Research
Houston, TX, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Newborn Screening Instruments Market By Test Type (Blood Spot Test, Hearing Test,...
12% CAGR of Medical Device Outsourcing Market Projected to Achieve US$ 352.3 billion by 2032 | Market.us
September 11, 2023 08:23 ET
|
Market.Us
New York, Sept. 11, 2023 (GLOBE NEWSWIRE) -- According to Market.us, The Global Medical Device Outsourcing Market size is projected to surpass around US$ 352.3 billion by 2032 from US$ 116.7 billion...
Global CAR T-Cell Therapy Market Size on a Meteoric Rise: Envisioning $2406.39 Million by 2030 with a Striking CAGR of 26.20%
August 23, 2023 04:51 ET
|
Zion Market Research
New York, NY, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “CAR T-Cell Therapy Market By Drug Type (Axicabtagene Ciloleucel, Brexucabtagene...
Mendus presenterar en uppdatering vid den 8:e årliga Innate Killer-konferensen avseende användningen av sin DCOne-plattform för att producera terapier baserade på högkvalitativa NK-celler
March 30, 2023 02:00 ET
|
Mendus AB
DCONE-DRIVEN EXPANSION AV MINNES-NK-CELLER LÄGGER GRUNDEN FÖR NYA EGENUTVECKLADE PIPELINEPROGRAM Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på immunterapier som tar sig...
Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit
March 30, 2023 02:00 ET
|
Mendus AB
DCONE-DRIVEN EXPANSION OF MEMORY NK CELLS BUILDS THE BASIS FOR NOVEL PROPRIETARY PIPELINE PROGRAM Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Mendus AB: Mendus presenterar flera abstracts på ASH 2022, inklusive en muntlig presentation av uppdaterade AML-överlevnadsresultat från fas 2-studien ADVANCE II
November 03, 2022 09:10 ET
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, eller “Bolaget”), ett bioläkemedelsföretag fokuserat på immunterapier som adresserar tumöråterfall, kan idag meddela att uppdaterade resultat från bolagets pågående...
Mendus AB: Mendus to present multiple abstracts at ASH 2022 including an oral presentation of updated AML survival results from the Phase 2 ADVANCE II trial
November 03, 2022 09:10 ET
|
Mendus AB
Mendus AB (“Mendus” publ; IMMU.ST, or “the Company”), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that updated results from the Company’s...